Drug Index

Sevelamer

 
print

Mechanism :

Sevelamer binds phosphate within the intestinal lumen, limiting absorption and decreasing serum phosphate concentrations.


Indication :

• Control of serum phosphorous


Contraindications :

Hypersensitivity to sevelamer or any component of the formulation; bowel obstruction: hypophosphatemia, active mucosal injury.


Dosing :

Safety and efficacy not established in children <6 years.

Body surface area (BSA) ≥0.75 to <1.2 sqm: 800 mg per meal; titrate as needed by 400 mg per dose at 2 week intervals.

BSA ≥1.2 sqm: 1,600 mg per meal; titrate as needed by 800 mg per dose at 2 week intervals.


Adverse Effect :

Metabolic acidosis, vomiting, nausea, diarrhea, dyspepsia, abdominal pain, constipation, flatulence, peritonitis.


Interaction :

Cyclosporine, Tacrolimus: Sevelamer may decrease the serum concentration of Cyclosporine.
Levothyroxine: Sevelamer may decrease the serum concentration of Levothyroxine.
Mycophenolate: Sevelamer may decrease the serum concentration of Mycophenolate.
Quinolones: Sevelamer may decrease the absorption of Quinolones.


07/14/2019 20:23:48 Sevelamer
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0